Scarica l'app Stockscreener
2.70
3.57%
-0.10
Dopo l'orario di chiusura:
2.69
-0.01
-0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.80
Aprire:
$2.83
Volume 24 ore:
492.33K
Relative Volume:
0.36
Capitalizzazione di mercato:
$463.37M
Reddito:
-
Utile/perdita netta:
$-54.70M
Rapporto P/E:
-8.1818
EPS:
-0.33
Flusso di cassa netto:
$-51.36M
1 W Prestazione:
-1.82%
1M Prestazione:
-12.05%
6M Prestazione:
-41.30%
1 anno Prestazione:
-45.34%
Intervallo 1D:
$2.69
$2.86
Intervallo di 1 settimana:
$2.59
$2.88
Portata 52W:
$2.59
$5.70
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Confronta SVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.70 | 463.37M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
Analysts Predict How High Savara Inc (SVRA) Will Go. - Stocks Register
JPMorgan Chase & Co. Purchases 13,420 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Molgramostim shows promise in rare lung disease treatment - MSN
SVRA stock touches 52-week low at $2.6 amid market challenges - MSN
Game-Changing Results: This Rare Disease Treatment Just Eliminated Need for Invasive Lung Procedures - StockTitan
Savara Announces Participation in Upcoming Healthcare Investor Conferences - The Bakersfield Californian
Rare Disease Pioneer Savara Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average PT from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Title: Savara Inc. Approves 2025 Executive Officers’ Target Bonus Amounts - Defense World
Savara sets executive bonus targets for 2025 - MSN
Savara sets executive bonus targets for 2025 By Investing.com - Investing.com Australia
Savara Sets 2025 Executive Bonus Targets - TipRanks
Savara Inc Updates Corporate Presentation in Latest SEC Filing - Defense World
Savara (NASDAQ:SVRA) Stock Price Down 5.3%Here's What Happened - MarketBeat
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference - MSN
Savara (NASDAQ:SVRA) Shares Up 8.1%Should You Buy? - MarketBeat
Barclays PLC Buys 158,244 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Highlights MOLBREEVI’s Potential in Rare Disease Market - TipRanks
Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses - Simply Wall St
Savara Inc (NASDAQ:SVRA) Shares Sold by Jane Street Group LLC - Defense World
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges By Investing.com - Investing.com South Africa
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges - Investing.com Australia
Savara Inc. Grants Inducement Awards to New Employees - MSN
Principal Financial Group Inc. Sells 7,607 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average Price Target from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Consensus Target Price from Analysts - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Geode Capital Management LLC Buys 264,825 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Barclays PLC Increases Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Who Really Pulls the Strings at Savara? Discover the Power Players! - Jomfruland.net
Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance
Savara Begins FDA Submission for Rare Lung Disease Treatment - MSN
State Street Corp Acquires 560,242 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
State Street Corp Purchases 560,242 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Strengthens Team with Strategic Equity Incentives: 200,000 Shares Awarded to New Hires - StockTitan
Savara (NASDAQ:SVRA) Earns “Market Outperform” Rating from JMP Securities - Defense World
Wells Fargo Initiates Coverage of Savara (SVRA) with Overweight Recommendation - MSN
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 6,141 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track (NASDAQ:SVRA) - Seeking Alpha
Savara (NASDAQ:SVRA) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Savara's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Australia
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):